Advertisement

Fibrolamellar Hepatocellular Carcinoma

  • Sanjay Kakar
Chapter
Part of the Molecular Pathology Library book series (MPLB, volume 5)

Abstract

Fibrolamellar hepatocellular carcinoma (FLM) is a rare tumor that occurs in young adults. It occurs in the absence of chronic liver disease or cirrhosis. Serum alpha-fetoprotein is typically normal. FLM is characterized by a triad of morphological features: polygonal tumour cells with eosinophilic cytoplasm, prominent nucleoli and lamellar pattern of fibrosis. A central scar is seen in some cases. FLM has to be distinguished from conventional hepatocellular carcinoma (HCC). Scirrhous variant of HCC can closely resemble FLM, but lacks its typical cytological features. Acinar differentiation and focal mucin production can be seen in FLM and can be confused with adenocarcinoma. Focal neuroendocrine differentiation occurs in a minority of FLMs and can be mistaken for neuroendocrine tumours. Some of the molecular changes typically observed in conventional HCC like p53 and beta-catenin mutations are not observed in FLM. FLM is an aggressive neoplasm with 5-year survival of around 50%. Although the prognosis in FLM has been described as favorable compared to conventional HCC, this is likely to be related to absence of cirrhosis rather than unique morphological features of the tumor.

Keywords

Epidermal Growth Factor Receptor Focal Nodular Hyperplasia Central Scar Noncirrhotic Liver Unique Morphological Feature 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. Am J Dis Child. 1956;91:168–86.Google Scholar
  2. 2.
    Craig J, Peters R, Edmondson H, et al. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinicopathologic features. Cancer. 1980;46:372–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Berman M, Libbey N, Foster J. Hepatocellular carcinoma: polygonal cell type with fibrous stroma – an atypical variant with a favorable prognosis. Cancer. 1980;46:1448–55.PubMedCrossRefGoogle Scholar
  4. 4.
    El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39:798–803.PubMedCrossRefGoogle Scholar
  5. 5.
    Ruffin IV MT. Fibrolamellar hepatoma. Am J Gastroenterol. 1990;85:577–81.PubMedGoogle Scholar
  6. 6.
    Klein WM, Molmenti EP, Colombani PM, et al. Primary liver carcinoma arising in people younger than 30 years. Am J Clin Pathol. 2005;124:512–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Cruz O, Laguna A, Vancells M, Krauel L, Medina M, Mora J. Fibrolamellar hepatocellular carcinoma in an infant and literature review. J Pediatr Hematol Oncol. 2008;30:968–71.PubMedCrossRefGoogle Scholar
  8. 8.
    Berman M, Sheahan D. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988;19:784–94.PubMedCrossRefGoogle Scholar
  9. 9.
    McLarney JK, Rucker PT, Bender GN, Goodman ZD, Kashitani N, Ros PR. Fibrolamellar carcinoma of the liver: radiologic-pathologic correlation. Radiographics. 1999;19:453–71.PubMedGoogle Scholar
  10. 10.
    Liu S, Chan KW, Wang B, Qiao L. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol. 2009;104:2617–24.PubMedCrossRefGoogle Scholar
  11. 11.
    Agarwal VR, Takayama K, Van Wyk JJ, Sasano H, Simpson ER, Bulun SE. Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J Clin Endocrinol Metab. 1998;83:1797–800.PubMedCrossRefGoogle Scholar
  12. 12.
    Kakar S, Burgart LJ, Batts KP, Garcia J, Jain D, Ferrell LD. Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis. Mod Pathol. 2005;18:1417–23.PubMedCrossRefGoogle Scholar
  13. 13.
    Ringe B, Wittekind C, Weimann A, Tusch G, Pichlmayr R. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet. 1992;175:299–305.PubMedGoogle Scholar
  14. 14.
    Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89–97.PubMedCrossRefGoogle Scholar
  15. 15.
    Paradinas FJ, Melia WM, Wilkinson ML, et al. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed). 1982;285:840–2.CrossRefGoogle Scholar
  16. 16.
    Collier NA, Weinbren K, Bloom SR, Lee YC, Hodgson HJ, Blumgart LH. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet. 1984;1:538–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Soyer P, Roche A, Levesque M, Legmann P. CT of fibrolamellar hepatocellular carcinoma. J Comput Assist Tomogr. 1991;15:533–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Brandt DJ, Johnson CD, Stephens DH, Weiland LH. Imaging of fibrolamellar hepatocellular carcinoma. Am J Roentgenol. 1988;151:295–9.CrossRefGoogle Scholar
  19. 19.
    Maniaci V, Davidson BR, Rolles K, Dhillon AP, Hackshaw A, Begent RH, et al. Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy. Eur J Surg Oncol. 2009;35:617–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Hadengue A, Thiers V, Santelli D, Bismuth H, Bréchot C. Presence of DNA sequences of hepatitis B virus in a fibrolamellar carcinoma of the liver. Gastroentérol Clin Biol. 1986;10:677–80.PubMedGoogle Scholar
  21. 21.
    Dadke D, Jaganath P, Krishnamurthy S, et al. The detection of HBV antigens and HBx-transcripts in an Indian fibrolamellar carcinoma patient: a case study. Liver. 2002;22:87–91.PubMedCrossRefGoogle Scholar
  22. 22.
    Morise Z, Sugioka A, Mizoguchi Y, et al. Fibrolamellar carcinoma of the liver in a Japanese hepatitis B virus carrier. J Gastroenterol Hepatol. 2005;20:1136–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Saul S, Titelbaum D, Gansler T, et al. The fibrolamellar variant of hepatocellular carcinoma; its association with focal nodular hyperplasia. Cancer. 1987;60:3049–55.PubMedCrossRefGoogle Scholar
  24. 24.
    Saxena R, Humphreys S, Williams R, et al. Nodular hyperplasia surrounding fibrolamellar carcinoma: a zone of arterialized liver parenchyma. Histopathology. 1994;25:275–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Hodgson HJ. Fibrolamellar cancer of the liver. J Hepatol. 1987;5:241–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Vecchio FM, Fabiano A, Ghirlanda G, et al. Fibrolamellar carcinoma of the liver: the malignant counterpart of focal nodular hyperplasia with oncocytic change. Am J Clin Pathol. 1984;81:521–6.PubMedGoogle Scholar
  27. 27.
    Farhi DC, Shikes RH, Murari PJ, Silverberg SG. Hepatocellular carcinoma in young people. Cancer. 1983;52:1516–25.PubMedCrossRefGoogle Scholar
  28. 28.
    Soreide O, Czerniak A, Bradpiece H, Bloom S, Blumgart L. Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and a review of the literature. Am J Surg. 1986;151:518–23.PubMedCrossRefGoogle Scholar
  29. 29.
    Pombo F, Rodriguez E, Arnal-Monreal F. Multicystic fibrolamellar hepatocellular carcinoma. CT appearance. Clin Imaging. 1993;17:67–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Tanaka J, Baba N, Arii S, et al. Typical fibrolamellar hepatocellular carcinoma in Japanese patients: report of two cases. Surg Today. 1994;24:459–63.PubMedCrossRefGoogle Scholar
  31. 31.
    Burgart LJ, Martinez CJM, Batts KP. Fibrolamellar hepatoma-importance of using a strict definition (abstract). Mod Pathol. 1994;7:129A.Google Scholar
  32. 32.
    Lack EE, Neave C, Vawter GF. Hepatocellular carcinoma. Review of 32 cases in childhood and adolescence. Cancer. 1983;52:1510–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Pérez-Guillermo M, Masgrau NA, García-Solano J, Sola-Pérez J, de Agustín y de Agustín P. Cytologic aspect of fibrolamellar hepatocellular carcinoma in fine-needle aspirates. Diagn Cytopathol. 1999;21:180–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Okada K, Kim YI, Nakashima K, et al. Fibrolamellar hepatocellular carcinoma coexistent with a hepatocellular carcinoma of common type: report of a case. Surg Today. 1993;23:626–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Okano A, Hajiro K, Takakuwa H, et al. Fibrolamellar carcinoma of the liver with a mixture of ordinary hepatocellular carcinoma: a case report. Am J Gastroenterol. 1998;93:1144–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Chang YC, Dai YC, Chow NH. Fibrolamellar hepatocellular carcinoma with a recurrence of classic hepatocellular carcinoma: a case report and review of Oriental cases. Hepatogastroenterology. 2003;50:1637–50.PubMedGoogle Scholar
  37. 37.
    Cheuk W, Chan JK. Clear cell variant of fibrolamellar carcinoma of the liver. Arch Pathol Lab Med. 2001;125:1235–8.PubMedGoogle Scholar
  38. 38.
    Pirisi M, Avellini C, Fabris C, et al. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol. 1998;124:397–400.PubMedCrossRefGoogle Scholar
  39. 39.
    Vecchio FM, Federico F, Dina MA. Copper and hepatocellular carcinoma. Digestion. 1986;35:109–14.PubMedCrossRefGoogle Scholar
  40. 40.
    Guigui B, Mavier P, Lescs MC, Pinaudeau Y, Dhumeaux D, Zafrani ES. Copper and copper-binding protein in liver tumors. Cancer. 1988;61:1155–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21:1011–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Garcia de Davila MT, Gonzalez-Crussi F, Mangkornkanok M. Fibrolamellar carcinoma of the liver in a child: ultrastructural and immunohistologic aspects. Pediatr Pathol. 1987;7:319–31.PubMedCrossRefGoogle Scholar
  43. 43.
    Górnicka B, Ziarkiewicz-Wróblewska B, Wróblewski T, et al. Carcinoma, a fibrolamellar variant – immunohistochemical analysis of 4 cases. Hepatogastroenterology. 2005;52:519–23.PubMedGoogle Scholar
  44. 44.
    Zhao M, Laissue JA, Zimmermann A. “Neuroendocrine” differentiation in hepatocellular carcinomas (HCCs): immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade. Histol Histopathol. 1993;8:617–26.PubMedGoogle Scholar
  45. 45.
    Omata M, Peters R, Tatters D. Sclerosing hepatic carcinoma: relationship to hypercalcemia. Liver. 1981;1:33–49.PubMedCrossRefGoogle Scholar
  46. 46.
    Fukunaga N, Fujioka A, Tanaka K, Toyama R. Oncocytic hepatocellular carcinoma with numerous globular hyaline bodies. Pathol Int. 1996;46:286–91.PubMedCrossRefGoogle Scholar
  47. 47.
    Balsara BR, Pei J, De Rienzo A, et al. Human hepatocellular carcinoma is characterized by a highly consistent pattern of genomic imbalances, including frequent loss of 16q23.1–24.1. Genes Chromosom Cancer. 2001;30:245–53.PubMedCrossRefGoogle Scholar
  48. 48.
    Poon TC, Wong N, Lai PB, et al. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology. 2006;131:1262–70.PubMedCrossRefGoogle Scholar
  49. 49.
    Marchio A, Pineau P, Meddeb M, et al. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene. 2000;19:3733–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Kakar S, Chen X, Ho C, et al. Chromosomal changes in fibrolamellar hepatocellular carcinoma detected by array comparative genomic hybridization. Mod Pathol. 2009;22:134–41.PubMedCrossRefGoogle Scholar
  51. 51.
    Lowichik A, Schneider NR, Tonk V, et al. Report of a complex karyotype in recurrent metastatic fibrolamellar hepatocellular carcinoma and a review of hepatocellular carcinoma cytogenetics. Cancer Genet Cytogenet. 1996;88:170–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Wilkens L, Bredt M, Flemming P, et al. Cytogenetic aberrations in primary and recurrent fibrolamellar hepatocellular carcinoma detected by comparative genomic hybridization. Am J Clin Pathol. 2000;114:867–74.PubMedCrossRefGoogle Scholar
  53. 53.
    Orsatti G, Greenberg PD, Rolfes DB, Ishak KG, Paronetto F. DNA ploidy of fibrolamellar hepatocellular carcinoma by image analysis. Hum Pathol. 1994;25:936–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Kannangai R, Wang J, Liu QZ, Sahin F, Torbenson M. Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Int J Gastrointest Cancer. 2005;35:53–60.PubMedCrossRefGoogle Scholar
  55. 55.
    Qin LX, Tang ZY, Ma ZC, Wu ZQ, Zhou XD, Ye QH, et al. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol. 2002;8:459–63.PubMedGoogle Scholar
  56. 56.
    Cieply B, Zeng G, Proverbs-Singh T, Geller DA, Monga SP. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology. 2009;49:821–31.PubMedCrossRefGoogle Scholar
  57. 57.
    Buckley AF, Burgart LJ, Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol. 2006;37:410–4.PubMedCrossRefGoogle Scholar
  58. 58.
    Kannangai R, Vivekanandan P, Martinez-Murillo F, Choti M, Torbenson M. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol. 2007;38:639–44.PubMedCrossRefGoogle Scholar
  59. 59.
    Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004;15:8421–5.CrossRefGoogle Scholar
  60. 60.
    Vivekanandan P, Micchelli ST, Torbenson M. Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. Hum Pathol. 2009;40:293–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Zhao P, Song X, Nin YY, Lu YL, Li XH. Loss of fragile histidine triad protein in human hepatocellular carcinoma. World J Gastroenterol. 2003;9:1216–9.PubMedGoogle Scholar
  62. 62.
    Kannangai R, Sahin F, Adegbola O, Ashfaq R, Su GH, Torbenson M. FHIT mRNA and protein expression in hepatocellular carcinoma. Mod Pathol. 2004;17:653–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Orsatti G, Hytiroglou P, Thung SN, Ishak KG, Paronetto F. Lamellar fibrosis in the fibrolamellar variant of hepatocellular carcinoma: a role for transforming growth factor beta. Liver. 1997;17:152–6.PubMedGoogle Scholar
  64. 64.
    Schoedel KE, Tyner VZ, Kim TH, Michalopoulos GK, Mars WM. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. Mod Pathol. 2003;16:14–21.PubMedCrossRefGoogle Scholar
  65. 65.
    Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol. 2003;163:1371–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Vivekanandan P, Torbenson M. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod Pathol. 2008;21:670–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Pinna AD, Iwatuski S, Lee RG, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantatation. Hepatology. 1997;26:877–83.PubMedCrossRefGoogle Scholar
  68. 68.
    Stevens WR, Johnson CD, Stephens DH, Nagorney DM. Fibrolamellar hepatocellular carcinoma: stage at presentation and results of aggressive surgical management. AJR Am J Roentgenol. 1995;164:1153–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Stipa F, Yoon SS, Liau KH, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106:1331–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Starzl TE, Iwatsuki S, Shaw Jr BW, et al. Treatment of fibrolamellar hepatoma with partial or total hepatectomy and transplantation of the liver. Surg Gynecol Obstet. 1986;162:145–9.PubMedGoogle Scholar
  71. 71.
    El-Gazzaz G, Wong W, El-Hadaty MK, et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transplant Int. 2000;13:S406–9.Google Scholar
  72. 72.
    Houben KW, McCall JL. Liver transplantation for hepatocellular carcinoma in patients without underlying liver disease: a systematic review. Liver Transpl Surg. 1999;5:91–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Bower M, Newlands ES, Habib N. Fibrolamellar hepatocellular carcinoma responsive to platinum-based combination chemotherapy. Clin Oncol (R Coll Radiol). 1996;8:331–3.CrossRefGoogle Scholar
  74. 74.
    Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21:421–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Spence RA, Rosen A, Krige JE, et al. Unresectable fibrolamellar hepatocellular carcinoma treated with intra-arterial lipiodolised doxorubicin. A case report. S Afr Med J. 1987;72:701–3.PubMedGoogle Scholar
  76. 76.
    Wood WJ, Rawlings M, Evans H, Lim CN. Hepatocellular carcinoma: importance of histologic classification as a prognostic factor. Am J Surg. 1988;155:663–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol. 2002;17:401–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Nagorney DM, Adson MA, Weiland LH, et al. Fibrolamellar hepatoma. Am J Surg. 1985;149:113–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Haas JE, Muczynski KA, Krailo M, Ablin A, Land V, Vietti TJ, et al. Histopathology and prognosis in childhood hepatoblastoma and hepatocarcinoma. Cancer. 1989;64:1082–95.PubMedCrossRefGoogle Scholar
  80. 80.
    Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003;97:2006–12.PubMedCrossRefGoogle Scholar
  81. 81.
    Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G. Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med. 1999;123:524–8.PubMedGoogle Scholar
  82. 82.
    Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. 2007;14:217–23.PubMedCrossRefGoogle Scholar
  83. 83.
    Lang H, Sotiropoulos GC, Dömland M, et al. Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Br J Surg. 2005;92:198–202.PubMedCrossRefGoogle Scholar
  84. 84.
    Zhao G, Su S, Borek D, Friesen S, Holmes F. Long survival and prognostic factors in hepatocellular carcinoma. J Surg Oncol. 1990;45:257–60.PubMedCrossRefGoogle Scholar
  85. 85.
    McPeake JR, O’Grady JG, Zaman S, Portmann B, Wight DG, Tan KC, et al. Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol. 1993;18:226–34.PubMedCrossRefGoogle Scholar
  86. 86.
    Moreno-Luna LE, Arrieta O, García-Leiva J, et al. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer. 2005;5:142.PubMedCrossRefGoogle Scholar
  87. 87.
    Ding SF, Delhanty JD, Bowles L, Dooley JS, Wood CB, Habib NA. Infrequent chromosome allele loss in fibrolamellar carcinoma. Br J Cancer. 1993;67:244–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Sirivatanauksorn Y, Sirivatanauksorn V, Lemoine NR, Williamson RC, Davidson BR. Genomic homogeneity in fibrolamellar carcinomas. Gut. 2001;49:82–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Anatomic PathologyUniversity of California, San Francisco and San Francisco VA Medical CenterSan FranciscoUSA

Personalised recommendations